Recombinant Immunotoxin and Use in Treating Tumors
Description of Invention:
The current invention relates to the 8H9 monoclonal antibody (MAb), which is highly reactive with a cell surface glycoprotein expressed on human breast cancers, childhood sarcomas, and neuroblastomas but is not reactive with the cell surface of normal human tissues. This specific reactivity suggests that this antibody could be useful as a diagnostic, or as a therapeutic molecule to treat breast cancer, osteosarcoma, and neuroblastoma. The PCT application claims the 8H9 protein, 8H9 antibodies, 8H9 immunotoxins, pharmaceutical compositions, and methods of use.
Inventors:
Ira Pastan (NCI) Masanori Onda (NCI) Nai-Kong Cheung (EM)
Patent Status:
DHHS Reference No. E-051-2003/0 --
PCT Application No. PCT/US03/38227 filed 01 Dec 2003, which published as WO 2004/050849 on 17 Jun 2004
U.S. Patent Application No. 10/537,061 filed 01 Jun 2005
Relevant Publication:
M. Onda et al., “In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma,” Cancer Res. 2004 Feb 15;64(4):1419-1424.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-MAb Based Cancer -Therapeutics-Immunoconjugates-Mab Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
